CompletedNCT05990075
This study is looking at analyze VHA electronic medical record data, to identify patient characteristics associated with poor treatment engagement for people with Depression. Participants receive a study treatment and complete follow-up visits and assessments.
In HinesDepressionBehavioralFrom 18 Years to 64 Years
- Countries
- United States
- Sponsor
- VA Office of Research and Development
- Condition
- Depression
CompletedEUCTR 2005-005597-67
This study is completed in Finland and in Slovakia. It focuses on depression.
In FinlandDepressionOther
- Countries
- Finland, Slovakia
- Sponsor
- sanofi-aventis recherche & développement
- Condition
- Depression
CompletedEUCTR 2007-003159-36
This study is completed in France, in Sweden, and in Finland. It is testing efficacy, safety, and tolerability of saredutant 100 mg once daily for Depression.
In SwedenDepressionOther
- Countries
- France, Sweden, Finland
- Sponsor
- sanofi-aventis recherche & développement
- Condition
- Depression
CompletedEUCTR 2005-003181-41
This study is completed in Austria, in Sweden, and in Estonia. It focuses on Anxiety.
In AustriaAnxietyOther
- Countries
- Austria, Sweden, Estonia
- Sponsor
- Sanofi-Synthelabo Recherche
- Condition
- Anxiety
CompletedEUCTR 2008-001718-26
This study is completed in Slovakia. It focuses on Depression.
In SlovakiaDepressionOther
- Countries
- Slovakia
- Sponsor
- Sanofi-Aventis Recherche & Développement
- Condition
- Depression
CompletedEUCTR 2006-003805-19
This study is completed in Belgium, in Sweden, in Finland, .... It focuses on Anxiety.
In SwedenAnxietyOther
- Countries
- Belgium, Sweden, Finland, ...
- Sponsor
- sanofi-aventis recherche et développement
- Condition
- Anxiety
TerminatedEUCTR 2006-004147-33
This study was terminated in Finland, in Austria, and in Slovakia. It is testing Fixed Dose of SR58611A 350 mg Twice a Day for Anxiety.
In FinlandAnxietyOther
- Countries
- Finland, Austria, Slovakia
- Sponsor
- sanofi-aventis recherche & développement
- Condition
- Anxiety
CompletedEUCTR 2006-001618-34
This study is completed in France and in Italy. It is testing clinical response of Duloxetine 60 mg and 120 mg per day for depression.
In ItalyDepressionOther
- Countries
- France, Italy
- Sponsor
- BOEHRINGER ING.
- Condition
- Depression
TerminatedNCT04174963
This summary needs review. Please check the official study record and contact the research team for details.
In ProvidenceMental healthBehavioralFrom 18 Years to 28 Years
- Countries
- United States
- Sponsor
- Rhode Island Hospital
- Condition
- Mental health
CompletedNCT01724125
This summary needs review. Please check the official study record and contact the research team for details.
In AtlantaMental healthOtherOver 18 Years
- Countries
- United States
- Sponsor
- Emory University
- Condition
- Mental health
CompletedNCT01455961
This study is completed. It is testing clinical Practice Treatment for Bipolarity.
Location not clearly listedBipolarityOther
- Countries
- Sponsor
- AstraZeneca
- Condition
- Bipolarity
CompletedNCT01309373
This study is completed. It is testing psychosocial and Symptomatic Remission and Community Integration Status for schizophrenia.
Location not clearly listedSchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Sponsor
- Janssen-Cilag, S.A.
- Condition
- Schizophrenia